Tricyclic Indazoles—A Novel Class of Selective Estrogen Receptor Degrader Antagonists
作者:James S. Scott、Andrew Bailey、David Buttar、Rodrigo J. Carbajo、Jon Curwen、Paul R. J. Davey、Robert D. M. Davies、Sébastien L. Degorce、Craig Donald、Eric Gangl、Ryan Greenwood、Sam D. Groombridge、Tony Johnson、Scott Lamont、Mandy Lawson、Andrew Lister、Christopher J. Morrow、Thomas A. Moss、Jennifer H. Pink、Radoslaw Polanski
DOI:10.1021/acs.jmedchem.8b01837
日期:2019.2.14
Herein, we report the identification and synthesis of a series of tricyclic indazoles as a novel class of selective estrogen receptor degrader antagonists. Replacement of a phenol, present in our previously reported tetrahydroisoquinoline scaffold, with an indazole group led to the removal of a reactive metabolite signal in an in vitro glutathione trapping assay. Further optimization, guided by X-ray
在这里,我们报告鉴定和合成的一系列三环吲唑作为一类新型的选择性雌激素受体降解拮抗剂。在我们以前报道的四氢异喹啉骨架中用吲唑基取代苯酚可以在体外谷胱甘肽捕获试验中去除反应性代谢产物信号。在X射线晶体结构和NMR构象工作的指导下,进一步的优化改变了烷基侧链和侧基芳基,从而导致化合物在人肝细胞中的转化率较低,并提高了化学稳定性。化合物9在药理学方面被描述为该系列的代表,并且证明了所需的雌激素受体α降解剂-拮抗剂概况并且在乳腺癌的异种移植模型中证明了活性。